These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28303523)

  • 1. Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States.
    Armstrong AW; Koning JW; Rowse S; Tan H; Mamolo C; Kaur M
    Clin Drug Investig; 2017 May; 37(5):493-501. PubMed ID: 28303523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data.
    Armstrong AW; Koning JW; Rowse S; Tan H; Mamolo C; Kaur M
    Dermatol Ther (Heidelb); 2017 Mar; 7(1):97-109. PubMed ID: 27905011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clearance of psoriasis: the impact of private versus public insurance.
    Buzney CD; Peterman C; Saraiya A; Au SC; Dumont N; Mansfield R; Gottlieb AB
    J Drugs Dermatol; 2015 Feb; 14(2):119-25. PubMed ID: 25689806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
    Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
    J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study.
    Christophers E; Segaert S; Milligan G; Molta CT; Boggs R
    J Dermatolog Treat; 2013 Jun; 24(3):193-8. PubMed ID: 22620684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER).
    Lambert J; Ghislain PD; Lambert J; Cauwe B; Van den Enden M
    J Dermatolog Treat; 2017 Aug; 28(5):394-400. PubMed ID: 27791446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.
    Feldman SR; Zhao Y; Shi L; Tran MH
    J Manag Care Spec Pharm; 2015 Oct; 21(10):874-88. PubMed ID: 26402388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
    Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
    Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
    J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
    Armstrong AW; Robertson AD; Wu J; Schupp C; Lebwohl MG
    JAMA Dermatol; 2013 Oct; 149(10):1180-5. PubMed ID: 23945732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Strober B; Gooderham M; de Jong EMGJ; Kimball AB; Langley RG; Lakdawala N; Goyal K; Lawson F; Langholff W; Hopkins L; Fakharzadeh S; Srivastava B; Menter A
    J Am Acad Dermatol; 2018 Jan; 78(1):70-80. PubMed ID: 29102053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
    Feldman SR; Evans C; Russell MW
    J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis.
    Svedbom A; Dalén J; Mamolo C; Cappelleri JC; Petersson IF; Ståhle M
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):215-223. PubMed ID: 24813476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis.
    Paller AS; Singh R; Cloutier M; Gauthier-Loiselle M; Emond B; Guérin A; Ganguli A
    J Drugs Dermatol; 2018 Feb; 17(2):187-194. PubMed ID: 29462227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A; Levi E
    J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining and treating moderate plaque psoriasis: a dermatologist survey.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2018 Nov; 29(7):658-663. PubMed ID: 29502473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis.
    Edson-Heredia E; Anderson S; Guo J; Zhu B; Malatestinic WN; Wine-Lee L; Swanson E
    Adv Ther; 2021 Jul; 38(7):3948-3961. PubMed ID: 34091866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
    Armstrong AW; Foster SA; Comer BS; Lin CY; Malatestinic W; Burge R; Goldblum O
    BMC Dermatol; 2018 Jun; 18(1):4. PubMed ID: 29954363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    PLoS One; 2020; 15(5):e0232738. PubMed ID: 32442204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.